HC Wainwright & Co. reiterates Buy rating on Clene, $31 price target

HC Wainwright & Co. maintained a Buy rating on Clene's stock with a $31 price target, implying a 900% upside from the Oct 16 close. The firm cited promising clinical data for CNM-Au8, showing reductions in biomarkers linked to ALS progression, and a strategic regulatory milestone with the NDA submission and planned Phase 3 trial.

Original reporting
Published Oct 19, 2026, 2:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 2:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. reiterates Buy rating on Clene, $31 price target — source image
Decision brief

The 30-second read

Med
01

Why it matters

The analyst’s reiteration adds a fresh catalyst that could attract speculative buying.

02

Market read

Analyst upgrade with a high price target may trigger short‑term buying pressure in CLNE.

03

What to watch

Regulatory timeline and potential competition in ALS therapies could temper upside.

Relevance 6/10Novelty 5/10Timing: today

Background

Clene is a micro‑cap biotech developing CNM‑Au8 for ALS, recently submitted an NDA and plans a Phase 3 trial.

Market effects

May lift sentiment for other ALS‑focused biotech stocks.

Limited to U.S. biotech sector; no broader market effect.

Low; relevance confined to investors tracking small‑cap biotech.

Counterpoint

Target may be overly optimistic given early‑stage data; risk of dilution if further financing needed.

Key entities

  • Clene Inc.

    Biotech firm developing CNM‑Au8 for ALS.

  • HC Wainwright & Co.

    Equity research firm that issued the Buy rating.

Related articles

$CLNNHigh

CLENE REPORTS Third QUARTER 2026 FINANCIAL RESULTS

Clene Inc. (CLNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CLENE REPORTS Third QUARTER 2026 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8 ® in amyotrophic lateral sclerosis (ALS